Tang Xiao, Lin Li, Yu Fangning, Ma Yizhao, Liu Zeyu, Xu Xuying
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, China.
World Allergy Organ J. 2025 Jun 3;18(7):101072. doi: 10.1016/j.waojou.2025.101072. eCollection 2025 Jul.
Allergic-related skin diseases, including atopic dermatitis (AD), urticaria, and contact dermatitis (CD), are significant global public health challenges. Currently, there is a lack of systematic analysis of allergic-related skin diseases globally.
This study aimed to quantify the global burden of AD, CD, and urticaria and evaluate their global epidemiology patterns. The Global Burden of Diseases (GBD) database was used to assess incidence, prevalence, and disability-adjusted life years (DALYs) for these allergic-related skin diseases. Additionally, the Bayesian Age-Period-Cohort (BAPC) model was employed to predict disease burden for the next 15 years.
From 1990 to 2021, cases of AD, CD, and urticaria rose steadily. In 2021, AD prevalence reached 129 million, a 20.02% increase from 1990. However, average annual percentage change (AAPC) values for the age-standardized prevalence rate (ASPR) of AD declined constantly (AAPC = -0.28). CD had the highest incidence, with 253 million new cases in 2021, though AAPC for ASPR of CD showed minimal changes. AD and urticaria peaked in early life, while CD peaked at ages 75-79. Moreover, AD had the strongest positive correlation with the Socio-demographic Index (SDI) ( = 2.2e-16, ρ = 0.626). AD, CD, and urticaria show the highest age-standardized rate in high, middle, and low-middle SDI regions, respectively, with all 3 conditions declining in high SDI. Health inequality analysis showed AD's burden is now more evenly distributed across SDI groups, while the global burden gap for urticaria and CD change limitedly.
Although the global disease burden of allergic-related skin diseases continues to rise, the overall age-standardized rates of AD have steadily declined and are projected to decrease further. In contrast, CD and urticaria require increased attention.
包括特应性皮炎(AD)、荨麻疹和接触性皮炎(CD)在内的过敏性皮肤病是全球重大的公共卫生挑战。目前,全球缺乏对过敏性皮肤病的系统分析。
本研究旨在量化AD、CD和荨麻疹的全球负担,并评估其全球流行病学模式。全球疾病负担(GBD)数据库用于评估这些过敏性皮肤病的发病率、患病率和伤残调整生命年(DALYs)。此外,采用贝叶斯年龄-时期-队列(BAPC)模型预测未来15年的疾病负担。
1990年至2021年,AD、CD和荨麻疹病例稳步上升。2021年,AD患病率达到1.29亿,比1990年增加了20.02%)。然而,AD年龄标准化患病率(ASPR)的年均变化百分比(AAPC)值持续下降(AAPC = -0.28)。CD发病率最高,2021年有2.53亿新发病例,不过CD的ASPR的AAPC变化极小。AD和荨麻疹在生命早期达到峰值,而CD在75-79岁达到峰值。此外,AD与社会人口指数(SDI)的正相关性最强( = 2.2e-16,ρ = 0.626)。AD、CD和荨麻疹分别在高、中、低中等SDI地区的年龄标准化率最高,在高SDI地区这三种疾病的发病率均呈下降趋势。健康不平等分析表明,AD的负担现在在SDI组中分布更加均匀,而荨麻疹和CD的全球负担差距变化有限。
尽管过敏性皮肤病的全球疾病负担持续上升,但AD的总体年龄标准化率稳步下降,预计还会进一步下降。相比之下,CD和荨麻疹需要更多关注。